* current or recent (within 10 days of screening) hospitalization for covid-19 infection * current or planned participation in another interventional trial to treat covid-19, at the discretion of the study principal investigator (pi) * current or recent use (within the last 14 days) of study drug or study drug/device combination * known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo * known contraindication(s) to study drug including prohibited concomitant medications * previous or current enrollment in the activ-6 trial

* current or recent (within 10 days of screening) hospitalization for covid-19 infection * current or planned participation in another interventional trial to treat covid-19, at the discretion of the study principal investigator (pi) * current or recent use (within the last 14 days) of study drug or study drug/device combination * known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo * known contraindication(s) to study drug including prohibited concomitant medications * previous or current enrollment in the activ-6 trial

current or recent (within 10 days of screening) hospitalization for covid-19 infection current or planned participation in another interventional trial to treat covid-19, at the discretion of the study principal investigator (pi) current or recent use (within the last 14 days) of study drug or study drug/device combination known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo known contraindication(s) to study drug including prohibited concomitant medications previous or current enrollment in the activ-6 trial

current or recent (within 10 days of screening) hospitalization for covid-19 infection current or planned participation in another interventional trial to treat covid-19, at the discretion of the study principal investigator (pi) current or recent use (within the last 14 days) of study drug or study drug/device combination known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo known contraindication(s) to study drug including prohibited concomitant medications previous or current enrollment in the activ-6 trial

- prior diagnosis of covid-19 infection (> 10 days from screening) - current or recent (within 10 days of screening) hospitalization - known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo - known contraindication(s) to study drug including prohibited concomitant medications

- prior diagnosis of covid-19 infection (> 10 days from screening) - current or recent (within 10 days of screening) hospitalization - known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo - known contraindication(s) to study drug including prohibited concomitant medications